Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial
Agusti et al.,
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection:..,
Enfermedades Infecciosas y Microbiología Clínica, doi:10.1016/j.eimc.2020.10.023
Small trial of low dose HCQ for healthcare workers with mild SARS-CoV-2 showing 68% lower progression to pneumonia, p = 0.21, and faster, but not statistically significant viral clearance. There were no ICU admissions or deaths. Prospective non-randomized study. The figures and supplementary data are not currently available in the pre-proof edition.
risk of progression, 68.4% lower, RR 0.32, p = 0.21, treatment 2 of 87 (2.3%), control 4 of 55 (7.3%), NNT 20, pneumonia.
|
time to viral-, 31.8% lower, relative time 0.68, treatment 87, control 55.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Agusti et al., 9 Dec 2020, prospective, Spain, peer-reviewed, median age 37.0, 13 authors, average treatment delay 5.0 days, dosage 400mg bid day 1, 200mg bid days 2-5.
Abstract: G Model
EIMC-2342; No. of Pages 7
ARTICLE IN PRESS
Enferm Infecc Microbiol Clin. 2020;xxx(xx):xxx–xxx
www.elsevier.es/eimc
Original Article
Efficacy and safety of hydroxychloroquine in healthcare professionals
with mild SARS-CoV-2 infection: Prospective, non-randomized trial
Antonia Agusti a,b , Elena Guillen a,b , Alfonso Ayora c , Andres Anton d,e , Cristina Aguilera a,b ,
Xavier Vidal a,b , Cristina Andres d,e , Manuel Alonso c , Meritxell Espuga c , Juliana Esperalba d,e ,
Ma Queralt Gorgas b,f , Benito Almirante g,h , Esteban Ribera g,h,∗
a
Clinical Pharmacology Service, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
Departament de Farmacologia, Terapèutica I Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
c
Occupational Health Service, Vall d’Hebron Hospital Universitari, Barcelona, Spain
d
Respiratory Viruses Unit, Microbiology Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
e
Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
f
Clinical Pharmacy Service, Vall d’Hebron Hospital Universitari, Barcelona, Spain
g
Infectious Diseases Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
h
Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
b
a r t i c l e
i n f o
Article history:
Received 1 September 2020
Accepted 29 October 2020
Available online xxx
Keywords:
SARS-CoV-2 infection
COVID-19
Hydroxychloroquine
Healthcare workers
Outpatients
a b s t r a c t
Objectives: To assess the efficacy and safety of hydroxychloroquine (HCQ) compared with no treatment
in healthcare workers with mild SARS-CoV-2 infection.
Methods: Prospective, non-randomized study. All health professionals with confirmed COVID-19
between April 7 and May 6, 2020, non-requiring initial hospitalization were asked to participate. Patients
who accepted treatment were given HCQ for five days (loading dose of 400 mg q12 h the first day followed
by200 mg q12 h). Control group included patients with contraindications for HCQ or who rejected treatment. Study outcomes were negative conversion and viral dynamics of SARS-CoV-2, symptoms duration
and disease progression.
Result: Overall, 142 patients were enrolled: 87 in treatment group and 55 in control group. The median
age was 37 years and 75% were female, with few comorbidities. There were no significant differences in
time to negative conversion of PCR between both groups. The only significant difference in the probability
of negative conversion of PCR was observed at day 21 (18.7%, 95%CI 2.0–35.4). The decrease of SARS-CoV2 viral load during follow-up was similar in both groups. A non significant reduction in duration of some
symptoms in HCQ group was observed. Two patients with HCQ and 4 without treatment developed
pneumonia. No patients required admission to the Intensive Care Unit or died. About 50% of patients
presented mild side effects of HCQ, mainly diarrhea.
Conclusions: Our study failed to show a substantial benefit of HCQ in viral dynamics and in resolution of
clinical symptoms in health care workers with mild COVID-19.
© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Enfermedades
Infecciosas y Microbiologı́a Clı́nica.
Eficacia y seguridad de hidroxicloroquina en profesionales sanitarios con
infección leve por SARS-CoV-2: Estudio..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit